Alopecia Areata

Below is a list of our alopecia areata studies that are currently enrolling.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata BRAVE-AA1

• Population: Black or African American Patients at least 18 years and ≤60 years for males (≤70 years of age for females)
• Study Condition: Severe Alopecia Areata
• Study Design: Participation in this research study will take approximately 61 weeks with 12 visits in that time. This research study includes three phases; a screening phase, treatment phase, and a follow-up phase. The length of the screening period varies from 5 to 35 days, depending on therapies that must be washed out or discontinued before initiation of treatment. Patients who meet all eligibility criteria will proceed to initiation of therapy and begin the 52 weeks open-label treatment. All subjects will take baricitinib 4mg once a day during the treatment period. The post-treatment follow-up visit will occur approximately 28 days after the last study drug dose.
• Compensation will be provided

 

Please contact Dr. Veronica Emmerich for more information regarding ongoing alopecia areata studies.

Email: emmerich@musc.edu

Phone: 843-876-0110